- What: Bristol-Myers Squibb is supporting the launch of an innovative structured donation programme – the Quick-Start initiative – targeted at people living with hepatitis C. Within this programme the company will donate its newly launched, patented medicine daclatasvir (Daklinza®).
- Objective: The aim of the programme is to cure hepatitis C among patients co-infected with hepatitis C virus (HCV) and HIV.
- Details: This programme will support governments to increase access to hepatitis C treatment until generic versions of the new direct-acting antivirals (DAAs), which present an effective cure for hepatitis C, enter the market.
- Scope: People co-infected with HCV and HIV in selected countries in Asia and Africa: Rwanda, Nigeria, Ethiopia, Myanmar, Vietnam and Indonesia.
In April 2016, Bristol-Myers Squibb announced its support of a programme aimed at curing hepatitis C among patients co-infected with HIV and HCV: the Quick-Start initiative. The programme is a partnership between Bristol-Myers Squibb, AmeriCares, the Clinton Health Access Initiative (CHAI) and Duke University. Bristol-Myers Squibb has agreed to provide enough of its new DAA Daklinza® to treat 10,000 patients.
The structured donation programme, which Bristol-Myers Squibb is in the process of launching, will support selected governments in Asia and Africa (Rwanda, Nigeria, Ethiopia, Myanmar, Vietnam and Indonesia) to increase access to hepatitis C treatment until generic versions of daclatasvir enter the market. A separate agreement made in January 2016 between Bristol-Myers Squibb and the Medicines Patent Pool will allow generic companies Cipla, Emcure, Hetero and Natco to produce and sell daclatasvir in 112 low- and middle-income countries.
This structured donation programme is considered innovative in the Access to Medicine Index 2016, as Bristol-Myers Squibb agreed to donate its newly launched, patented medicine Daklinza®, whereas most structured donation programmes donate older, off-patent products.